Get App
Aurobindo Pharma > Company History > Pharmaceuticals > Company History of Aurobindo Pharma - BSE: 524804, NSE: AUROPHARMA

Aurobindo Pharma

BSE: 524804|NSE: AUROPHARMA|ISIN: INE406A01037|SECTOR: Pharmaceuticals
Feb 19, 16:00
102.05 (20.4%)
VOLUME 897,415
Feb 19, 15:59
101.45 (20.27%)
VOLUME 28,738,121
Company History - Aurobindo Pharma
 - The company was incorporated on 26th December as a Private Limited
 company and was converted into a Public Limited company with effect
 from 30-4-1992.  The company is registered with the Registrar of
 Companies, Andhra Pradesh at Hyderabad.  The chief promoters of the
 Company are Shri P.V. Ramaprasad Reddy and Shri K. Nityananda Reddy.
 - Aurobindo Pharma Limited is one of the leading manufacturers of
 saving anti-biotic bulk drugs in India with excellent track record
 profitability and growth.
 - The Company has developed inhouse technology for manufacture of
 bulk drugs as well as formulations.
 - The Company is one of the largest manufacturers of Ampicillin and
 Cloxacillin in India.
 - Another unit was also set up for the manufacture of CMIC Chloride,
 bulk drug intermediate at Pashamylaram, near Hyderabad.  Through
 another Company namely, Chaitanya Organics Pvt. Ltd., which is now
 being merged with Aurobindo Pharma Limited.
 - The Company issued Bonus Shares in the ratio of 1:1 in May, in the
 ratio of 2:1 in June, 1993 and in the ratio of 7:20, in November
 - The Company follows the Mercantile System of Accounting and
 recognises Income and Expenditure on Accrual basis.
 - The Company has set up two more units during the year, viz.,
 - i) Bulk drug unit at Bollaram, near Hyderabad.
 - ii) Formulations unit at Kukatpally, near Hyderabad.
 - The Company is setting up a Bulk Drug cum Formulation Plant to
 produce sterile Bulk Drugs like Ampicillin Sodium (Sterile) IP/BP,
 Cloxacillin Sodium (Sterile) IP/BP, and cephalosporins (Sterile)
 Drugs and Formulations in the dosage forms like sterile powder
 injectables, small volume parenterals, Capsules and Tablets.
 - The installed capacity of the Pondicherry Unit of the Company is
 increased from 204 TPA to 300 TPA during the current year
 - The Bollaram unit is for the manufacture of anti-biotic bulk
 namely Cloxacillin, and Dicloxacillin mainly for exports.
 - During the Year, the Company has upgraded the plant and increased
 installed capacity from 78 TPA to 84 TPA.  The Company has set up a
 separate block in the same premises during the current year, 1994-95
 for manufacture of high value drugs namely Astemizole, Domeperidone,
 Famotidine and Omeprazole, with an installed capacity of 9 TPA.
 - The Kukatpally unit is for manufacture of pharmaceutical
 with an installed capacity of 360 lakhs tablets and 480 lakhs
 per annum.
 - During the current year the Company has increased the installed
 capacity of the merged company Chaitanya Organics Pvt. Ltd., from
 TPA to 144 TPA.  Further a new bulk drug intermediate namely DCMIC
 Chloride is also manufactured in this unit from April.  The Company
 also expanded the above unit by setting up a separate block for
 manufacture of Norfloxacillin and Pefloxacillin with an installed
 capacity of 60 TPA.
 - The Company proposed to acquire two generators of 250 KVA capacity
 each as standby arrangement.
 - The company has entered into domestic formulations market in 5
 and plans to launch in other states shortly.
 - The Company has agency set-up at Srilanka, Thailand, Russia and
 Nigeria for marketing its products.  It proposes to set up its own
 marketing offices at Hongkong, Moscow and Nigeria to promote bulk
 - The Company has a connected power load of 500 KVA from A.P.S.E.B. 
 addition, 3 Generators of 125 KVA capacity each have been installed
 a stand by arrangement.
 - The Company is a member of Patancheru Effluent Treatment Plant
 Limited and Jeedimetle Effluent Treatment Plant.
 - All the Assets and Liabilities of M/s. Chaitanya Organics Pvt. 
 will be taken over by M/s. Aurobindo Pharma Ltd. with effect from
 April, on completion of amalgamation formalities.
 - As per the scheme of amalgamation it is proposed to issue one
 share of M/s. Aurobindo Pharma Ltd. of Rs 10/- each credited as
 paid up for every one equity share of Rs 10/- each fully paid up
 in M/s. Chaitanaya Organics Pvt. Ltd. to the Shareholders of M/s.
 Chaitanya Organics Pvt. Ltd.
 - In January, Videocon International and Videocon Appliances sold a
 tranche of Aurobindo shares to the public at a premium of Rs 180.
 - Glaxo (India), the Indian subsidiary of the UK-based
 is understood to be negotiating with the Hyderabad-based Aurobindo
 Pharma for an alliance to meet its global bulk drug requirements.
 - The annual capacities now stand at 300 million of capsules and 840
 tonnes of bulk drugs.
 - The company proposes to manufacture fourth generation
 such as 7-ACA, cephalexin, cephatoxime and cephazolin.
 - AUROBINDO Pharma Ltd is setting up two wholly-owned subsidiaries
 the US and Hong Kong to increase its presence in the international
 - The company is one of the largest bulk manufacturers of
 semi-synthetic penicillin (SSP) products such as ampicilin and
 Amoxycillin.  It is the world's fourth largest producer of
 and fifth largest producer of amoxycillins.
 - The company has also launched new formulations like auronim
 Suspension in the paediatric segment.
 - The company has obtained the shareholders permission to invest
 ,00,000 in the share capital of Aurobindo Pharma (Miami) Inc in
 and 0,000 in the share capital of Aurobindo Pharma (Hong Kong)
 - The company would be launching several new formulations including
 Roxythromycin, Clarithromycin, Sporfloxocyin, besides Sephradin, a
 smei-synthetic, in the domestic market.  Among sterile products to
 launched by the company are Cephazolin, Cehatoxin and Azithromycin.
 - The Hyderabad-based Aurobindo Pharma had received in-principle
 approval from the Board of Industrial and Financial Reconstruction
 (BIFR) in March to buy the plant.
 - APL is today the most cost-efficient producer of SSPs in India and
 low cost international producer of other value added bulk drugs and
 drug intermediaries.
 - Aurobindo currently manufactures three types of drugs including
 cephalosporin-based formulations, drugs for gastroenterology and
 pain-related products.
 - The company proposes to deploy the issue proceeds to part-finance
 R&D thrust and the growth of its formulations business.  APL plans
 meet the further funds requirement for its capital expenditure
 programme, if any, through internal accruals.
 - The board of directors has allotted 5,51,000 equity shares of
 each at a premium of Rs.480 per share by private placement on
 preferential basis to FIIs, FIs, MFs and bodies corporate etc.
 - Aurobindo Pharma Ltd, the largest domestic manufacturer of
 penicillin-based bulk antibiotics, plans to form joint ventures in
 Brazil and China by the end of financial year 1999-2000
 - Aurobindo Pharma Ltd. a major producer of semi-synthetic
 in the country, proposes to set up two joint venture companies in
 US to manufacture cephalosporins and non-cephalosporins.
 - Aurobindo Pharma is setting up two joint ventures for formulations
 the US, with an investment of  million.
 - As per the scheme of Amalgamation equity shares of Aurobindo
 Limited will be exchanged to the shareholders of Sri Chakra Remedies
 Limited for every 100 equity shares held by them.
 - The Company has launched an exclusive anti-viral division --
 -- to educate and to provide preventive drug care for HIV/AIDS
 in the country.
 - Hyderabad based Aurobindo Pharma has restructured its management
 responsibilities in view of major growth initiatives to be taken to
 create a platform for penetrating attractive global markets. P V
 Ramaprasad Reddy, former managing director, has been appointed
 executive chairman, while K Nityananda Reddy, former joint managing
 director and co-promoter, has been appointed managing director, APL
 informed the Bombay Stock Exchange on July 4.
 -This new structure is expected to enable the company to concentrate
 the strategies of change being pursued by it to achieve the goal of
 becoming a research and development-based international
 company, it said, adding that the changes had received board
 -Aurobindo Pharma Ltd today announced the launch two more drugs--
 Efavirenz (Viranz) and Nelfinavir (NELVEX)-- for the treatment of
 -Three existing Directors, Mr Srinivas Lanka, Mr A J Kamath and Mr A
 Siva Rama Prasad have stepped down from the directorship, thus
 room for appointment of independent external directors. Accordingly,
 their resignations were accepted. While Mr Srinivas Lanka will be
 considered for reappointment as non-executive independent Director,
 A J Kamath will assume the responsibility of group financial
 Further, it is planned to retain the services of Mr A Siva Rama
 for group operations.
 -Aurobindo Pharma to allot further equity shares/warrants to
 -Srinivas Lanka re-inducted into the Board of Aurobindo Pharma.
 -Sathyamurthy appointed as Additional Director of Aurobindo Pharma.
 -The Board of Directors of Aurobindo Pharma Ltd has approved the
 appointment of Dr K A Balasubramanian as an additional director on
 the Board of Directors of the company. Dr Balasubramanian shall be an
 independent, non-executive director.
 -Aurobindo informed BSE that Citadel Aurobindo Biotech Ltd, a 50:50
 Joint venture company
 introduced Aztreonam a Monabactam Betalactam antibiotic for the first
 time in the Indian
 Pharma Market with a brand name 'TREONAM'.
 -Aurobindo Tongling (Datong) pharmaceuticals Ltd, China , a JV
 between APL and Shanxi Tongling Pharmaceuticals co. has set up for
 manufacture of pharmaceutical products for the local market.
 -With a view to manufacture Pen G, a raw material essential for the
 production of semi-synthrtic
 pencillin, Aurobindo has infused Rs 59cr in a flagship
 Aurobindo(Datong) Pharma Ltd.
 -Aurobindo Pharma has launched second joint venture company in US for
 the purpose
 of Research and Development.
 -Allots 950,000 equity shares to promoters/directors by way of
 conversion of warrants
 -Aurobindo Pharma has launched second joint venture company in the
 United States for the purpose of R & D in alliance with Salus
 -Aurobindo Pharma has filed around 20 patents in the areas of central
 nervous system, cardio-vascular, and anti-cholesterol segments. Out of
 this it is able to obtain 2 of them in United States of America.
 -UTI sold 3 pc stake from the company
 -Board approves the issue on a preferential basis, of an aggregate
 upto 3,100,000 equity shares of Rs.5/- each at a price of Rs.302/-
 per equity share (including a premium of Rs.297 per equity share),
 totalling up to Rs.93.62 cr
 -Company ropes in Merlion India Fund 1, Mauritius, for allotting 31
 lakh equity shares on a preferential basis at a price of Rs 302 per
 share, including a premium of Rs 297 per share, totalling Rs 93.62
 - Ms P. Suneela Rani, has sold 6,80,000 equity shares of Rs 5 each of
 the company, constituting 1.4 per cent of equity of its current
 paid-up equity of Rs 24.2 crore. These shares were sold in the open
 market from December 23-31 last year
 Aurobindo Pharma Ltdhas announced that it has received its first
 Certificate of Suitability (CoS) approval from the European
 Directorate for Quality Medicines (EDQM) for its product in the
 therapeutic segment of gastroenterology. 
 -Aurobindo Pharma Ltd has informed that the members at the EGM of the
 Company held on December 26, 2003 have unanimously approved the
 following special resolution : 'Issue of equity shares under
 preferential allotment guidelines of SEBI'. Further, the Company has
 also informed that delisting of securities of the company from
 Ahmedabad Stock Exchange was approved w.e.f. January 15, 2004.
 -Aurobindo Pharma Ltd has informed that pursuant to the application
 of the Company, its securities have been removed from the list of the
 Ahmedabad Stock Exchange (ASE) w.e.f. January 15, 2004.
 -USFDA part of Department of health and human science approves UNIT
 VIII facility as a site to manufacture APIs for the US Market.
 -Aurobindo AIDS drug receives US FDA clearance
 -Aurobindo Pharma gets EDQM approval for Flucloxacillin Sodium
 -Aurobindo Pharma receives approval for Sertraline Hydrochloride
 -Aurobindo Pharma receives approval for Cephalexin Capsules by US
 -Aurobindo's receives final approval of Mirtazapine Orally
 Disintegrating Tablets
 -Aurobindo Pharma receives final approval of Mirtazapine ODT 45mg for
 US marketAurobindo Pharma receives final approval of Mirtazapine ODT
 45mg for US market
 -Aurobindo Pharma Ltd has announced that the US FDA has granted
 tentative approval for the Company's Simvastatin Tablets USP 5 mg, 10
 mg, 20 mg, 40 mg and 80 mg
 -Aurobindo receives US FDA approval for Didanosine (Chewable)
 -Aurobindo Pharma Ltd has announced that it has received the
 marketing authorization approval from Medicines Evaluation Board
 (MEB), NETHERLANDS for Mirtazapine 15, 30 and 45 mg orally
 disintegrating tablets containing the active ingredient Mirtazapine.
 -Aurobindo Pharma Ltd has appointed Mr. A.Mohan Rami Reddy as Company
 Secretary of the Company.
 -Aurobindo Pharma receives final approval for SIMVASTATIN tablets
 from USFDA.
 -Aurobindo arm acquires Dutch firm Pharmacin.
 - Aurobindo Pharma Ltd has received one more approval from USFDA for
 Cefadroxil capsules 500 mg.
 - Aurobindo Pharma Ltd has announced that on June 13, 2007 the
 Company unveiled their new Logo and Corporate Identity at a ceremony
 in Hyderabad.
 - Aurobindo Pharma Ltd has announced that the Company has received an
 approval from the US Food & Drug Administration to market its 300mg
 Cefdinir Capsules in the US market. The drug falls under the
 Anti-bacterial segment and is a generic equivalent of Abbott
 Laboratories, OMNICEF.
 -Aurobindo Pharma Ltd has appointed Mr. K Raghunathan as an
 Additional Director of the Company at the Board Meeting held on
 January 30, 2008.
 - Aurobindo Pharma Ltd has announced that the Company has been
 awarded ARV contract worth Rs 70 crores for 3 products which are WHO
 / USFDA pre-qualified by National Aids Control Organization (NACO).
 - Aurobindo Pharma Ltd has got final clearance from the US Food and
 Drug Administration (USFDA) to manufacture and market Didanosine
 Delayed Release capsules in 125 mg, 200 mg, 250 mg and 400 mg. The
 drug is indicated for treatment of HIV - 1 infections in adults. It
 is the generic version of Bristol Myer Squibb's Videx EC
 delayed-release capsules.
 - Aurobindo Pharma Ltd has received Swissmedic approvals for
 Amlodipine Besylate Tablets and Metformin Hydrochloride Tablets.
 - Aurobindo Pharma has received final approval from the United States
 Food and Drug Administration for its product Ceftazideme injection in
 different dosages.
 Aurobindo Pharma receives USFDA tentative approval for Famciclovir
 -Aurobindo Pharma Announces Strategic Divestment of Aurobindo
 (Datong) Bio Pharma, China
 -Aurobindo Pharma receives USFDA tentative approval for Levofloxacin
 -Aurobindo Pharma receives USFDA tentative approval for Venlafaxine
 Extended Release Capsules.
 -Aurobindo Pharma receives USFDA tentative approval for Famclclovir
 -Aurobindo Pharma receives Platinum Certificate of Outstanding
 Exports Award from Pharmexcil.
 -Company has splits its Face value of Shares from Rs 5 to Re 1
 -Aurobindo Pharma receives final approvals for Quetiapine Fumarate
 -Aurobindo Pharma receives final approval for Olanzapine Tablets.
 -Aurobindo Pharma gets USFDA nod for anti-HIV drugs Lamivudine and
 -Aurobindo Pharma gets USFDA nod to launch Clopidogrel tablets
 -Aurobindo Pharma receives final approval for Metformin Hydrochloride
 Extended Release Tablets.
 -Aurobindo Pharma gets USFDA approval for anti-migraine tablets.
 - Aurobindo Pharma receives tentative approval for
 Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Tablets.
 -Aurobindo gets final USFDA approval for Cefadroxil oral suspension.
 -Aurobindo Pharma bags final US FDA approval for Rizatriptan Benzoate
 -Aurobindo completes the acquisition of Natrol.
 -Aurobindo Pharma receives USFDA Approval for Amoxicillin for Oral
 -Aurobindo completes the acquisition of select Western European
 Businesses of Actavis.
 -Aurobindo Pharma receives USFDA Approval for Divalproex Sodium
 Extended-Release Tablets.
 -Aurobindo Pharma receives USFDA approval for Repaglinide Tablets.
 - Aurobindo Pharma has received approval from the USFDA to
 manufacture and market Valsartan Tablets USP
 -Aurobindo Pharma gets USFDA nod for Lacosamide Tablets
 -Aurobindo Pharma receives USFDA Tentative Approval for Lacosamide
 -Aurobindo Pharma gets USFDA nod for Lacosamide Tablets
 -Aurobindo Pharma gets USFDA nod for Sildenafil injection
 -Aurobindo gets USFDA nod for Atracurium Besylate injections
 -Aurobindo Pharma receives USFDA Approval for Cefixime for Oral
 Suspension USP
 -Aurobindo Pharma receives USFDA approval for Famotidine Tablets
 --The Company has allotted the Bonus Shares in the Ratio of 1:1.
 -Aurobindo Pharma receives USFDA Approval for Norethindrone Acetate
 -Aurobindo Pharma receives USFDA Approval for Tranexamic Acid
 -Aurobindo Pharma receives approval for Voriconazole Tablets
 -Aurobindo Pharma receives USFDA Approval for Celecoxib Capsules
 -Aurobindo Pharma bags approval for Acetylcysteine Injection
 -Aurobindo Pharma receives approval for Naproxen Tablets
 -Aurobindo Pharma receives USFDA Approval for Pantoprazole Sodium for
 -Aurobindo receives approval for Amlodipine & Valsartan Tablets
 -Aurobindo Pharma receives USFDA Approval for Hydromorphone
 Hydrochloride Tablets
 -Aurobindo Pharma receives USFDA Approval for Levetiracetam in Sodium
 Chloride Injection.
 -Aurobindo's European Subsidiary Signs Binding Agreement to Acquire
 Generis Farmaceutica SA in Portugal.
 -Aurobindo Pharma Forays into Biosimilars Development through an
 acquisition of Four Products from TL Biopharmaceutical AG.
 -Aurobindo Pharma receives USFDA Approval for Atomoxetine Capsules.
Source : Dion Global Solutions Limited
Quick Links for Aurobindo Pharma
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of is prohibited.